Frederic Bard

Education

• PhD École normale supérieure de Lyon (1995 — 1999)
• PhD Yale University School of Medicine (1995 — 1998)

Companies

• Directeur de Recherche Centre national de la recherche scientifique (2022)
• Visiting Scientist A*STAR - Agency for Science, Technology and Research (2022)
• Founder and CEO Albatroz Therapeutics (2020)
• Chief Innovation Officer at IMCB A*STAR - Agency for Science, Technology and Research (2020 — 2021)
• Senior Principal Investigator at IMCB A*STAR - Agency for Science, Technology and Research (2013 — 2021)
• Program Coordinator: M3: Multi Modal Molecular Biology Division of IMCB A*STAR - Agency for Science, Technology and Research (2016 — 2020)
• Adjunct Assistant Professor National University of Singapore (2007 — 2020)
• Principal Investigator A-STAR (2006 — 2013)
• Principal Investigator Institute of Molecular and Cell Biology (2006 — 2013)

Skills

• Protein Chemistry
• PCR
• Drug Discovery

Other

High Throughput Screening, Bioinformatics, In Vitro, Protein Expression, Molecular Cloning, Life Sciences, Transfection, Microscopy, Genomics, Cancer Research, Western Blotting, Lifesciences, Cell, Cell Culture, Fluorescence Microscopy, Biochemistry, Confocal Microscopy, Molecular Biology, Cell Biology